Clinical trial · Observational

commd7 Gene Expression in ALL

The Copper Metabolism MURR1 Domain 7 (COMMD7) Gene Expression in Acute Lymphoblastic Leukemia

NCT05592470CI-TRIAL-00061636unknownClinicalTrials.gov clinicaltrialsPublishedExplore in graph →

Summary

Brief summary (as posted)

* study the expression pattern of COMMD7 gene in acute lymphoblastic leukemia. * investigate correlation between the expression level of COMMD7 gene with other diagnostic parameters and prognosis in ALL .

Conditions

Conditions (1)

Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.

Condition (as posted)	Mapped entity	Match	Confidence
ALL	Acute Lymphoblastic Leukemia	ALIAS	0.90

Interventions

Interventions (1)

Intervention	Type	Mapped drug	Match
Reverse transcription-quantitative polymerase chain reaction (RT-qPCR).	Diagnostic Test	—	UNRESOLVED

Design

Arms and outcomes

Arms (2)

label
PATEINTS
description
51 patients newly diagnosed with acute lymphoblastic leukemia
interventionNames
1. Diagnostic Test: Reverse transcription-quantitative polymerase chain reaction (RT-qPCR).
label
controls
description
51 normal persons
interventionNames
1. Diagnostic Test: Reverse transcription-quantitative polymerase chain reaction (RT-qPCR).

Primary outcomes (1)

measure
The expression pattern of COMMD7 gene in acute lymphoblastic leukemia
timeFrame
BASELINE
description
Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) TO DETECT EXPRESSION pattern in ALL

Eligibility

Eligibility (as posted)

Sex: All

Show eligibility criteria text

Inclusion Criteria:

* Patients newly diagnosed with acute lymphoblastic leukemia , male or female at any age.

Exclusion Criteria:

* history of anti-neoplastic therapy, such as chemotherapy or radiotherapy.
* Any other types of cancers.
* Any clinically systemic acute or chronic inflammatory disease/s within one months.

References

Publications (7)

BACKGROUNDGarza-Veloz I, Martinez-Fierro ML, Jaime-Perez JC, Carrillo-Sanchez K, Ramos-Del Hoyo MG, Lugo-Trampe A, Rojas-Martinez A, Gutierrez-Aguirre CH, Gonzalez-Llano O, Salazar-Riojas R, Hidalgo-Miranda A, Gomez-Almaguer D, Ortiz-Lopez R. Identification of differentially expressed genes associated with prognosis of B acute lymphoblastic leukemia. Dis Markers. 2015;2015:828145. doi: 10.1155/2015/828145. Epub 2015 Feb 24. PMID 25802479
BACKGROUNDShort NJ, Kantarjian H, Jabbour E. Optimizing the treatment of acute lymphoblastic leukemia in younger and older adults: new drugs and evolving paradigms. Leukemia. 2021 Nov;35(11):3044-3058. doi: 10.1038/s41375-021-01277-3. Epub 2021 Jun 25. PMID 34172894
BACKGROUNDBartuzi P, Hofker MH, van de Sluis B. Tuning NF-kappaB activity: a touch of COMMD proteins. Biochim Biophys Acta. 2013 Dec;1832(12):2315-21. doi: 10.1016/j.bbadis.2013.09.014. Epub 2013 Sep 29. PMID 24080195
BACKGROUNDBurstein E, Hoberg JE, Wilkinson AS, Rumble JM, Csomos RA, Komarck CM, Maine GN, Wilkinson JC, Mayo MW, Duckett CS. COMMD proteins, a novel family of structural and functional homologs of MURR1. J Biol Chem. 2005 Jun 10;280(23):22222-32. doi: 10.1074/jbc.M501928200. Epub 2005 Mar 30. PMID 15799966
BACKGROUNDYou N, Li J, Gong Z, Huang X, Wang W, Wang L, Wu K, Zheng L. COMMD7 functions as molecular target in pancreatic ductal adenocarcinoma. Mol Carcinog. 2017 Feb;56(2):607-624. doi: 10.1002/mc.22520. Epub 2016 Jul 8. PMID 27350032
BACKGROUNDYou N, Li J, Huang X, Wu K, Tang Y, Wang L, Li H, Mi N, Zheng L. COMMD7 promotes hepatocellular carcinoma through regulating CXCL10. Biomed Pharmacother. 2017 Apr;88:653-657. doi: 10.1016/j.biopha.2017.01.046. Epub 2017 Jan 29. PMID 28142122
BACKGROUNDLi K, Chen L, Zhang H, Wang L, Sha K, Du X, Li D, Zheng Z, Pei R, Lu Y, Tong H. High expression of COMMD7 is an adverse prognostic factor in acute myeloid leukemia. Aging (Albany NY). 2021 Apr 23;13(8):11988-12006. doi: 10.18632/aging.202901. Epub 2021 Apr 23.